{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T02:59:22Z","timestamp":1720321162280},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["#287625"],"award-info":[{"award-number":["#287625"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.peptides.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T22:03:40Z","timestamp":1494021820000},"page":"106-107","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neuromedin peptides\u2014Potential for anti-obesity drug candidates?"],"prefix":"10.1016","volume":"94","author":[{"given":"Miia","family":"Kovalainen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2017.05.001_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.peptides.2015.04.010","article-title":"inhibits food intake partly by inhibiting gastric emptying","volume":"69","author":"Dalb\u00f8ge","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.05.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2016.02.009","article-title":"FDA-approved anti-obesity drugs in the United States","volume":"129","author":"Daneschvar","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.peptides.2017.05.001_bib0015","doi-asserted-by":"crossref","first-page":"25831","DOI":"10.3390\/ijms161025831","article-title":"Site-specific PEGylation of therapeutic proteins","volume":"16","author":"Dozier","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2017.05.001_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.pharep.2017.01.009","article-title":"Neuromedin: an insight into its types, receptors and therapeutic opportunities","volume":"69","author":"Gajjar","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.peptides.2017.05.001_bib0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1900\/RDS.2011.8.355","article-title":"Peptides and their potential role in the treatment of diabetes and obesity","volume":"8","author":"Greenwood","year":"2011","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.peptides.2017.05.001_bib0030","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.bmc.2017.02.023","article-title":"A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects","volume":"25","author":"Inooka","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.peptides.2017.05.001_bib0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/pr.113.008367","article-title":"Novel delivery systems for improving the clinical use of peptides","volume":"67","author":"Kovalainen","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2017.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.peptides.2007.02.009","article-title":"PEGylation of cholecystokinin prolongs its anorectic effect in rats","volume":"28","author":"Le\u00f3n-Tamariz","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.05.001_bib0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1373\/clinchem.2014.231753","article-title":"A multifunctional neuropeptide with pleiotropic roles","volume":"61","author":"Martinez","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.peptides.2017.05.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2017.04.001","article-title":"PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration","author":"Masuda","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2017.05.001_bib0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","article-title":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.peptides.2017.05.001_bib0060","doi-asserted-by":"crossref","first-page":"824305","DOI":"10.1155\/2012\/824305","article-title":"Obesity and appetite control","volume":"2012","author":"Suzuki","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/j.peptides.2017.05.001_bib0065","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cmdc.201600374","article-title":"Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation","volume":"11","author":"van Witteloostuijn","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.peptides.2017.05.001_bib0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrd3830","article-title":"The pharmaceutical market for obesity therapies","volume":"11","author":"Wong","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.peptides.2017.05.001_bib0075","series-title":"Obesity and overweight fact sheet","author":"World Health Organization","year":"2016"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978117301924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978117301924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T23:21:56Z","timestamp":1535844116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978117301924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":15,"alternative-id":["S0196978117301924"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2017.05.001","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromedin peptides\u2014Potential for anti-obesity drug candidates?","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}